[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100483608":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":10,"centralContacts":21,"locations":32,"responsibleParty":48,"collaborators":10,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":52,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":10,"studyType":64,"phases":10,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":35,"whyStopped":10,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Assistance Publique - Hôpitaux de Paris","OTHER",[8,13],{"label":9,"type":10,"description":10,"interventionNames":11},"Before antidepressant treatment",null,[12],"Other: functional magnetic resonance imaging",{"label":14,"type":10,"description":10,"interventionNames":15},"After antidepressant treatment",[12],[17],{"type":6,"name":18,"description":19,"armGroupLabels":20,"otherNames":10},"functional magnetic resonance imaging","Patients treated with ketamine antidepressants will be tested with fMRI before or 24h after a single ketamine infusion administered in the clinical setting.",[14,9],[22,28],{"name":23,"role":24,"phone":25,"phoneExt":26,"email":27},"Philippe FOSSATI, PUPH","CONTACT","+33142162891","+33","philippe.fossati@aphp.fr",{"name":29,"role":24,"phone":30,"phoneExt":26,"email":31},"Liane Schmidt, PhD","33157274374","liane.schmidt@icm-institute.org",[33],{"facility":34,"status":35,"city":36,"state":10,"zip":10,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"GH Pitié Salpêtrière","RECRUITING","Paris","France","FR",{"type":40,"coordinates":41},"Point",[42,43],2.3488,48.85341,{"lat":43,"lon":42},[46],{"name":47,"role":24,"phone":10,"phoneExt":10,"email":10},"Philippe Fossati, PU-PH",{"type":49,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100483608","belief-updating-in-treatment-resistant-depression-100483608",false,"NCT05577247","Belief Updating in Treatment Resistant Depression","How the Brain Encodes Beliefs: A Functional Magnetic Resonance Imaging Study of the Belief Updating in Treatment Resistant Depression.","KETABELIEF","Inclusion Criteria:\n\nDemographic criteria:\n\n* Age: 18 to 70 years\n* Male et female\n\nDiagnostic criteria, severity and clinical course:\n\n* Major depressive disorder (MDD) according to the DSM5 criteria\n* MADRS≥20,\n* Treatment resistant depression (TRD) defined by failure to respond to at least two trials of different antidepressant treatments\n* affiliation of a social security regime\n\nTreatments\u002Fstrategies\u002Fprocedures:\n\no At the start of new antidepressant treatment involving glutamate receptor modulators.\n\nExclusion criteria:\n\nCriteria relating to associated pathologies carrying specific risks:\n\n* Mental disorder other than MDD: personality disorder type borderline, schizophrenia\n* Inability to understand the task instructions and to perform the behavioral task\n* Mini Mental Score (MMS) ≤ 25\n* Antidepressant treatment involving dopaminergic agonists, and Monoamine oxidase inhibitors (MAOI)\n* Neurological comorbidities : epilepsy, brain tumor, non-corrected visual and\u002For auditory deficit\n\nCriteria associated with contraindications\u002Fprocedures\u002Finterventions added by the research:\n\no Contra-indications for an MRI exam (metallic implant, pacemaker, artificial heart valve, brain vascular malformation, aneurysm clips, exposed by metallic fragments, artificial implants, peripheral or neuronal stimulator, insulin pump, intravenous catheter, epilepsy, metallic contraceptive device, claustrophobia, unwillingness to be informed in case of abnormal MRI (with a significant medical anomaly))\n\nCriteria relating to vulnerable populations:\n\n* Pregnancy\n* Patient on AME (state medical aid)\n* Patient under guardianship, curators or legal protection","ALL","18 Years","70 Years",{"count":62,"type":63},60,"ESTIMATED","OBSERVATIONAL","Major depressive disorder (MDD) is characterized by a cognitive triad of negative beliefs about oneself, the future and the world. For example, depressed patients hold persistently negative expectations about the future, despite contradictory evidence, and these strong negative beliefs are thought to play an important role in the maintenance of depressive symptoms and potentially in treatment resistance. Indeed, one out of three patients with major depressive disorder does not respond to conventional, monoaminergic treatments, which has led to the concept of treatment resistant depression (TRD). It is unknown how the brain encodes the strong negative beliefs that are insensitive to positive disconfirming information in TRD patients, and how these neural underpinnings of maladaptive belief updating are altered by antidepressant treatment.\n\nThe principal objective of this study is to gain insight into the brain mechanisms of belief updating about the future in TRD patients before and after starting ketamine treatment. The results of this study are expected to provide a better understanding of the neurocognitive mechanisms of belief-updating in depressed patients, and how these mechanisms contribute to clinical improvement following ketamine antidepressant treatment.",[67],"Treatment Resistant Depression",[69,70,71,72],"Treatment resistant depression","belief updating","fMRI","ketamine","2026-04-08",{"date":75,"type":76},"2026-04-13","ACTUAL",{"date":78,"type":76},"2024-05-13",{"date":80,"type":63},"2026-12-13",{"name":5,"class":6},1]